Luseogliflozin

From Wikipedia, the free encyclopedia
Luseogliflozin
Luseogliflozin.svg
Clinical data
Trade namesLusefi
Other namesTS-071
ATC code
Legal status
Legal status
  • Rx-only in Japan
Identifiers
CAS Number
PubChem CID
DrugBank
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H30O6S
Molar mass434.55 g·mol−1
3D model (JSmol)
  • CCOC1=CC=C(C=C1)CC2=C(C=C(C(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)CO)O)O)O)OC)C

Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus.[1][2] It was approved for use in Japan in 2014.[1]

References[]

  1. ^ a b Markham A, Elkinson S (June 2014). "Luseogliflozin: first global approval". Drugs. 74 (8): 945–50. doi:10.1007/s40265-014-0230-8. PMID 24848756. S2CID 1770988.
  2. ^ Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, et al. (September 2017). "Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study". Clinical Pharmacology in Drug Development. 6 (5): 439–447. doi:10.1002/cpdd.364. PMID 28783873.
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by .

  • v
  • t
Retrieved from ""